NCT03618030View on ClinicalTrials.gov

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL

Enrollment

288

Participants

Timeline

Start Date

August 21, 2018

Primary Completion Date

July 5, 2019

Study Completion Date

July 5, 2019

Conditions

ADHD

Interventions

DRUG

PRC-063 oral capsules

Daily dose

DRUG

Placebo oral capsules

Daily dose

Trial Locations (8)

17004

Penn State Health Milton S. Hershey Medical Center, Hershey

27705

Center for Psychiatry and Behavioral Medicine, Durham

32751

Meridien Research Inc., Maitland

33805

Meridien Research, Lakeland

34201

Meridien Research Inc., Bradenton

77007

Bayou City Research, Houston

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas

02043

South Shore Psychiatric Services, Hingham

All Listed Sponsors

lead

Purdue Pharma, Canada

INDUSTRY

NCT03618030 - PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter